Technical Analysis for RNAC - Cartesian Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | -3.48% | |
| 50 DMA Resistance | Bearish | -3.48% | |
| 180 Bearish Setup | Bearish Swing Setup | -3.48% | |
| Wide Bands | Range Expansion | -3.48% | |
| Gapped Up | Strength | -3.48% | |
| Lower Bollinger Band Walk | Weakness | -8.78% | |
| Outside Day | Range Expansion | -8.78% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Possible Inside Day | about 18 hours ago |
| Up 3% | about 20 hours ago |
| Up 2% | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.6 |
| 52 Week Low | 11.665 |
| Average Volume | 113,338 |
| 200-Day Moving Average | 20.01 |
| 50-Day Moving Average | 19.45 |
| 20-Day Moving Average | 19.53 |
| 10-Day Moving Average | 18.28 |
| Average True Range | 1.86 |
| RSI (14) | 39.39 |
| ADX | 18.55 |
| +DI | 18.98 |
| -DI | 19.59 |
| Chandelier Exit (Long, 3 ATRs) | 17.85 |
| Chandelier Exit (Short, 3 ATRs) | 21.09 |
| Upper Bollinger Bands | 23.17 |
| Lower Bollinger Band | 15.88 |
| Percent B (%b) | 0.15 |
| BandWidth | 37.34 |
| MACD Line | -0.78 |
| MACD Signal Line | -0.41 |
| MACD Histogram | -0.3761 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.97 | ||||
| Resistance 3 (R3) | 19.16 | 18.68 | 18.63 | ||
| Resistance 2 (R2) | 18.68 | 18.16 | 18.58 | 18.51 | |
| Resistance 1 (R1) | 17.81 | 17.85 | 17.57 | 17.62 | 18.40 |
| Pivot Point | 17.33 | 17.33 | 17.21 | 17.23 | 17.33 |
| Support 1 (S1) | 16.46 | 16.81 | 16.22 | 16.27 | 15.48 |
| Support 2 (S2) | 15.98 | 16.50 | 15.88 | 15.37 | |
| Support 3 (S3) | 15.11 | 15.98 | 15.25 | ||
| Support 4 (S4) | 14.92 |
